In August 2024, the United States Patent and Trademark Office (USPTO) issued new guidance on the use of artificial intelligence (AI) in precision medicine and AI-related patent eligibility. This guidance aims to clarify the criteria for AI-related patents, particularly in the context of human-AI collaborations. The recent updates reflect the USPTO's approach to AI innovations, which is crucial for stakeholders in the fields of technology and intellectual property.